Arbutus Biopharma Corporation
ABUS
$4.31
-$0.08-1.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 51.49% | -406.86% | 110.29% | -95.71% | 36.44% |
| Total Depreciation and Amortization | 0.00% | 0.00% | -96.67% | -0.90% | -0.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -457.72% | 1,876.74% | -100.78% | 162.00% | 84.70% |
| Change in Net Operating Assets | 56.35% | 106.30% | -446.18% | 2,400.87% | 90.84% |
| Cash from Operations | 19.55% | 63.06% | -17.61% | -29.82% | 50.26% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.87% | -164.22% | 37.47% | -15.91% | 212.61% |
| Cash from Investing | 86.42% | -164.18% | 37.55% | -15.38% | 211.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 94.31% | 86.31% | -83.73% | 95.92% | -19.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 94.31% | 86.31% | -83.73% | 95.92% | -19.94% |
| Foreign Exchange rate Adjustments | 108.33% | -157.14% | 425.00% | 112.12% | -760.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.67% | -4,565.48% | -54.96% | -83.36% | 114.49% |